Integrative Analyses of Saturation CRISPR Protein Scan
Integrative Analyses of Saturation CRISPR Protein Scan
批准号:
10058930
负责人:
Chun-Wei David Chen
金额:
$13.2万
依托单位国家:
美国
项目类别:
财政年份:
2019
资助国家:
美国
项目状态:
已结题
起止时间:
2019-04-01 至 2022-03-31
关键词:
3-DimensionalART proteinAchievementAcute leukemiaAllelesAwardBioconductorChromatinClinicalClustered Regularly Interspaced Short Palindromic RepeatsDataData AnalysesData SetDatabasesDevelopmentDiseaseDockingElementsEnvironmentEpigenetic ProcessFundingFusion Oncogene ProteinsFutureGene ExpressionGene RearrangementGenetic ScreeningGenetic TranscriptionGenomicsGoalsHistone H3HistonesHumanKDM1A geneKnowledgeLeadLigandsLysineMLL geneMalignant NeoplasmsMethodsMethyltransferaseNUP98 geneNatureParentsPatientsPharmacologic SubstancePhase I Clinical TrialsPhosphotransferasesPlayProteinsReaderRegimenResearchRoleScanningSurvival RateT-Cell LymphomaTertiary Protein StructureTherapeuticThree-dimensional analysisTreatment EfficacyValidationWorkanalysis pipelinebasecBioPortalcancer typechromatin modificationclinical databaseclinically relevantcomputational pipelinesdensityexperimental studyfunctional genomicsgenome integrityimprovedinformatics toolinhibitor/antagonistinnovationinsightleukemialeukemogenesismutantnovelnovel therapeuticsoutcome forecastp38 Mitogen Activated Protein Kinaseprogramsresponsetargeted treatmenttherapeutic candidatetherapeutic developmenttherapeutic targettooltrial design
中文摘要
点击翻译按钮获取中文摘要
英文摘要
PROJECT SUMMARY/ABSTRACT
Epigenetic mechanisms play a critical role in controlling gene expression during normal development and are
often altered in disease states, particularly in cancer. MLL-rearranged (MLL-r) leukemias account for 5-10%
of human acute leukemia and is associated with poor prognosis. The unmet clinical needs and the lack of
effective targeted therapy to the MLL-r leukemias emphasize the need for novel regimens. Recent cancer
epigenetics studies discovered a central role for the histone H3 lysine 79 (H3K79) methyltransferase
DOT1L in MLL-r leukemogenesis. Important clinical responses have been noted with DOT1L inhibitor
treatment as a single agent, however, it is expected that combination treatments will be necessary.
Our preliminary studies proposed in the parent award R01 CA236626 based on a high-density CRISPR
genetic screen of DOT1L have identified the potential of “saturation CRISPR protein scan” in de novo
functional domain discovery. The objective of this Revision Application is to establish a computational pipeline
to facilitate the data analyses of the saturation CRISPR protein scan. Our central hypothesis is that saturation
CRISPR protein scan data harbor clinically impactful information that can be further explored through adaptation
of the integrative informatics tools from the ITCR Program. We will (Aim 1) integrate the saturation CRISPR
protein scan with cBioPortal (an integrative clinical genomic database; funded by ITCR) to identify clinically
relevant alleles, and (Aim 2) streamline the saturation CRISPR protein scan with DINC 2.0 (a parallelized meta-
docking method for the incremental docking of large ligands; funded by ITCR) to identify lead epigenetic ligands
to the CRISPR defined hotspots.
This study is innovative because (1) it introduces a novel concept of using saturation CRISPR genetic
screens for epigenetic ligand discovery, and (2) it establishes an analysis pipeline for a novel field that
bridges the functional genomics, protein domain identification, and therapeutics discovery.
The impact of this research will be of significance because (1) it immediately provides novel therapeutic
opportunities against the difficult-to-treat MLL-r leukemias, and (2) the computational pipeline established
in this proposal and streamlined with the ITCR supported integrative informatics tools will help identify novel
functional elements for future pharmaceutical targeting in multiple types of cancers.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Mechanism and therapeutic opportunities of targeting the Tudor domain
-
批准号:10606365
-
项目类别:
-
资助金额:$51.09万
-
财政年份:2022
-
负责人:Chun-Wei David Chen
-
依托单位:
Role of BAZ2A in MLL-r leukemia and therapeutic response
-
批准号:10593927
-
项目类别:
-
资助金额:$38.78万
-
财政年份:2019
-
负责人:Chun-Wei David Chen
-
依托单位:
Role of BAZ2A in MLL-r leukemia and therapeutic response
-
批准号:10356863
-
项目类别:
-
资助金额:$39.57万
-
财政年份:2019
-
负责人:Chun-Wei David Chen
-
依托单位:
Combinational targeting the feed forward epigenetic circuitry in mixed lineage leukemia
-
批准号:10531876
-
项目类别:
-
资助金额:$38.78万
-
财政年份:2018
-
负责人:Chun-Wei David Chen
-
依托单位:
Combinational targeting the feed forward epigenetic circuitry in mixed lineage leukemia
-
批准号:10306337
-
项目类别:
-
资助金额:$39.57万
-
财政年份:2018
-
负责人:Chun-Wei David Chen
-
依托单位:
Combinational targeting the feed forward epigenetic circuitry in mixed lineage leukemia
-
批准号:10059184
-
项目类别:
-
资助金额:$39.57万
-
财政年份:2018
-
负责人:Chun-Wei David Chen
-
依托单位:
Epigenetic mechanisms for oncogene silencing in MLL-rearranged leukemia
-
批准号:9532338
-
项目类别:
-
资助金额:$24.9万
-
财政年份:2017
-
负责人:Chun-Wei David Chen
-
依托单位:
Epigenetic mechanisms for oncogene silencing in MLL-rearranged leukemia
-
批准号:9324564
-
项目类别:
-
资助金额:$12.39万
-
财政年份:2016
-
负责人:Chun-Wei David Chen
-
依托单位: